Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
November 26th, 2008
GeoVax Labs, Inc. (BULLETIN BOARD: GOVX) ("GeoVax" or "the Company"), a biopharmaceutical firm developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, announced its third quarter 2008 financial results and provided an operational update. Robert McNally, GeoVax's President and CEO, commented, "We are very pleased with the progress we've made during the third quarter of 2008 and for the year so far, as we've taken steps to address both short-term and long-term goals. We made a shipment of the vaccine to the HIV Vaccine Trials Network during October, which is a significant step in preparation for the largest...
Source: Vaccine Weekly (2008-11-26)
|
